Street Calls of the Week
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (NASDAQ:APGE), a $2.17 billion biotech company, sold 2,725 shares of common stock on September 3, 2025, for approximately $103,198. According to InvestingPro analysis, the company’s shares are currently trading near their Fair Value.
The sales were executed in two transactions. In the first transaction, 2,535 shares were sold at a weighted average price of $37.82, with prices ranging from $37.39 to $38.37. The second transaction involved the sale of 190 shares at a weighted average price of $38.55, with prices ranging from $38.54 to $38.55. Notably, analysts maintain a Strong Buy consensus on the stock, with price targets ranging from $87 to $116. InvestingPro subscribers can access 7 additional key insights about APGE’s financial health and growth prospects.
Following these transactions, Dambkowski directly owns 233,548 shares of Apogee Therapeutics .
The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
In other recent news, Apogee Therapeutics has captured attention with its latest developments. The company reported its second-quarter earnings, prompting Goldman Sachs to reiterate its Early-Stage Biotech rating. Apogee has updated its catalyst timeline, expecting Phase 1 data for its respiratory treatments in the coming quarters. In addition, Apogee’s Phase 2a trial data for its atopic dermatitis treatment, APG777, has been met with positive reactions from several investment firms. Stifel maintained its Buy rating and set a price target of $95.00, citing the treatment’s efficacy and safety profile comparable to existing options. Jefferies also raised its price target to $96.00, highlighting the promising trial data. Canaccord Genuity reaffirmed its Buy rating and $89.00 price target, noting the successful proof-of-concept results. Citi echoed similar sentiments, maintaining its Buy rating and emphasizing the trial results as a significant de-risking event for APG777. These developments underscore a period of active clinical progress and investor interest in Apogee Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.